Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2004-03-01
2009-10-06
Helms, Larry R. (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S004000, C435S007230
Reexamination Certificate
active
07598042
ABSTRACT:
A novel prostate cancer marker is described that is found in cancerous and normal prostate cells of individuals that have prostate cancer but is not found in the prostate of individuals without prostate cancer. The marker also is present in normal tissue adjacent to tumor tissue in individuals having prostate cancer. The marker, however, is absent in the prostate of individuals without prostate cancer. Methods employing the novel prostate cancer marker of the invention to predict the occurrence of the prostate disease, monitor the progression of prostate cancer and effect the treatment of prostate cancer, also are described.
REFERENCES:
patent: 4882268 (1989-11-01), Penman et al.
patent: 4885236 (1989-12-01), Penman et al.
patent: 5273877 (1993-12-01), Fey et al.
patent: 5308835 (1994-05-01), Clements
patent: 5547928 (1996-08-01), Wu et al.
patent: RE35747 (1998-03-01), Penman et al.
patent: 5824490 (1998-10-01), Coffey et al.
patent: 5849509 (1998-12-01), Coffey et al.
patent: 5866535 (1999-02-01), Getzenberg et al.
patent: 5874539 (1999-02-01), Coffey et al.
patent: 5989826 (1999-11-01), Beausang et al.
patent: 6132968 (2000-10-01), Le et al.
patent: 6162608 (2000-12-01), Beausang et al.
patent: 6174528 (2001-01-01), Cooper et al.
patent: 6410247 (2002-06-01), Beausang et al.
patent: 2003/0228640 (2003-12-01), Getzenberg
patent: 5-146294 (1993-06-01), None
patent: WO 87/03910 (1987-07-01), None
patent: WO 93/09437 (1993-05-01), None
patent: WO 94/00573 (1994-01-01), None
patent: WO 94/18222 (1994-08-01), None
patent: WO 95/16919 (1995-06-01), None
patent: WO 97/16206 (1997-09-01), None
patent: WO 01/29218 (2001-04-01), None
Getzenberg et al., Cancer Res. vol. 51, p. 6514-6520, 1991.
search result-1.
search result Le et al.
Getzenberg et al., Cancer Res. vol. 51, p. 6514-6520, 1991.
search result-1 (2008).
search result Le et al., (2008).
MPSRCH search result, 2007, us-11-080-836.5.rpr.result 3.
MPSRCH search result, 2007, us-11-080-836.5.max—30.rai, result 36.
International Search Report.
Database Genbank pBlueskript KS+ Jan. 29, 2002, XP002292954, Retrieved from NCBI Database accession No. X52331, Nucleotides 772-1287 encode a polypeptide matching amino acids 23-194 of Seq ID 6 *Abstract.
Konety B R et al. “Characterization of a metastatic Dunning rat prostate tumor specific nuclear matrix protein (NMP) AM-1”, Proceedings of the Annual Meeting of the American Association for Cancer Research, New York NY US, vol. 37, 1996, p. 73, XP002172068, ISSN: 0197-016X, Abstract.
Anderson et al., “Qualitative Analysis of Coomassie-Blue-Stained Proteins From Normal Prostate, Benign Prostatic Hypertrophy, or Adenocarcinoma of the Prostate, Separated by Two-Dimensional Protein Electrophoresis,”The Prostate, 1985, pp. 315-323, vol. 6.
Bejany, D.E., et al., Malignant Vesical Tumors Following Spinal Cord Injury,The Journal of Urology, vol. 138, pp. 1390-1392 (1987).
Berezney, R., et al., “Identification of a Nuclear Protein Matrix”,Biochemical and Biophysical Research Communications, vol. 60, No. 4 (1974).
Cech, T.R., PhD., “Ribozymes and Their Medical Implications”,JAMA, vol. 260, No. 20, pp. 3030-3034 (1988).
Celis et al., “Expression of the transformation-sensitive protein “cyclin” in normal human epidermal basal cells and simian virus 40-transformed keratinocytes,” Proc. Natl Acad. Sci. USA, vol. 81, pp. 3128-3132 (1984).
Celis et al., “Intermediate filaments in monkey kidney TC7 cells: Focal centers and interrelationship with other cytoskeletal systems,” Proc. Natl Acad. Sci. USA, vol. 81, pp. 1117-1121 (1984).
Cupo, J., “Electrophoretic analysis of nuclear matrix proteins and the potential clinical applications”,Elsevier Science Publishers B. V., pp. 389-406 (1991).
Diener, E., et al., “Specific Immunosuppression by Immunotoxins Containing Daunomycin”,Science, vol. 231, pp. 148-150 (1986).
DiScipio et al., “Nucleotide sequence of cDNA and derived amino acid sequence of human complement component C9,” Proc. Natl Acad. Sci. USA, vol. 81, pp. 7298-7302 (1984).
Douillard et al., “Monoclonal Antibodies Specific Immunotherapy of Gastrointestinal Tumors,” Hybridoma, vol. 5, Suppl. 1 (1986) pp. S139-S149.
Eberharter A., et al., “Nuclear Matrix of the lower eukaryotePhysarum polycephalumand the mammalian epithelialLLC-PK1cell line—A comprehensive investigation of different preparation procedures”, vol. 212, No. 2 pp. 573-580 (1992). (XP02068893).
El-Masri, W.S., “Bladder Cancer After Spinal Cord Injury”,International Medical Society of Paraplegia, pp. 265-270 (1981).
Fey, E.G., et al., “Epithelial Cytoskeletal Framework and Nuclear Matrix-Intermediate Filament Scaffold: Three-dimensional Organization and Protein Composition”,The Journal of Cell Biology, vol. 98, pp. 1973-1984 (1984).
Fey, E.G., et al., “Nuclear matrix proteins reflect cell type of origin in cultured human cells”,Proc. Natl. Acad. Sci. USA, vol. 85, pp. 121-125 (1988).
Fey, E.G., et al., “The Nuclear Matrix: Defining Structural and Functional Roles”,Eukaryotic Gene Expression, pp. 127-143 (1991).
Fey, E.G., et al., “Tumor promoters induce a specific morphological signature in the nuclear matrix-intermediate filament scaffold of Madin-Darby canine kidney (MDCK) cell colonies”,Proc. Natl. Acad. Sci. USA, vol. 81, pp. 4409-4413 (1984).
Fradet Y., “Molecular and immunologic approaches in the management of bladder cancer,” Urologic Clinics of North America, vol. 18, No. 3, pp. 515-524 (1991) (XP000881253).
Fraley et al., “New Generation liposomes: the engineering of an efficient vehicle for intracellular delivery of nucleic acids,” Trends Biochem. Sci., vol. 6, pp. 77-80 (1981).
Geisler, W.O., et al., “Survival in Traumatic Transverse Myelitis”,Paraplegia, vol. 14, pp. 262-275 (1977).
Getzenberg et al., “Modifications of the Intermediate Filament and Nuclear Matrix Networks by the Extracellular Matrix,”Biochemical and Biophysical Research Communications, Aug. 30, 1991, pp. 340-344, vol. 179, No. 1.
Getzenberg et al., “Tissue Specificity on the Hormonal Response in Sex Accessory Tissues Is Associated with Nuclear Matrix Protein Patterns,”Mol. Endo., 1990, pp. 1336-1342, vol. 4, No. 9.
Getzenberg, R. H., “Nuclear Matrix and the Regulation of Gene Expression: Tissue Specificity”,Journal of Cellular Biochemistry, vol. 55, pp. 22-31 (1994).
Getzenberg, R., et al., “Bladder Cancer-associated Nuclear Matrix Proteins”,Cancer Researchvol. 56, No. 7, pp. 1690-1694, (1996). (XP002068894).
Getzenberg, R.H., et al., “Identification of Nuclear Matrix Proteins in the Cancer and Normal Rat Prostate”,Cancer Research, vol. 51, pp. 6514-6520 (1991).
Gordon, J.N., et al., “Altered Extracellular Matrices Influence Cellular Processes and Nuclear Matrix Organizations of Overlying Human Bladder Urothelial Cells”, Cancer Research, vol. 53, pp. 4971-4977 (1993).
Greiner, J.W., “Recombinant Interferon Enhances Monoclonal Antibody—Targeting of Carcinoma Lesions in Vivo”,Reports, pp. 895-898 (1987).
Hackler, R.H., “A 25-Year Prospective Mortality Study In The Spinal Cord Injured Patient: Comparison With The Long-Term Living Paraplegic”,The Journal of Urology, vol. 117, pp. 486-488 (1977).
Haseloff, J., et al., “Simple RNA enzymes with new and highly specific endoribonuclease activities”,Nature, vol. 334, pp. 585-591 (1988).
Huse, W.D., et al., “Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda”,Research Article, pp. 1275-1281 (1989).
Kaufman, J.M., et al., “Bladder Cancer and Squamous Metaplasia in Spinal Cord Injury Patients”, pp. 967-971 (1977).
Keesee, S.K., et al., “Utilization of Nuclear Matrix Proteins for Cancer Diagnosis”,Critical Reviews in Eukaryoti
Bent Stephen A.
Foley & Lardner LLP
Helms Larry R.
Snader Shaun R.
University of Pittsburgh of the Commonwealth System of Higher Ed
LandOfFree
Early prostate cancer antigens (EPCA), polynucleotide... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Early prostate cancer antigens (EPCA), polynucleotide..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Early prostate cancer antigens (EPCA), polynucleotide... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4143152